Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 389, Issue 8, 2016, Pages 819-830

  Fahmi, Alaa N A ^a   Shehatou, George S G ^a   Shebl, Abdelhadi M ^b   Salem, Hatem A ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Cisplatin; Febuxostat; Inflammation; Kidney injury; Oxidative stress; TNF

Indexed keywords

CISPLATIN; CREATININE; FEBUXOSTAT; GLUTATHIONE; LACTATE DEHYDROGENASE; MALONALDEHYDE; NITRATE; NITRIC OXIDE; NITRITE; PROTEIN; SERUM ALBUMIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UREA; URIC ACID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AUTACOID; BIOLOGICAL MARKER; ENZYME INHIBITOR; TUMOR NECROSIS FACTOR; URINARY TRACT AGENT; XANTHINE OXIDASE;

ACUTE KIDNEY TUBULE NECROSIS; ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL VACUOLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; ENZYME ACTIVITY; HISTOPATHOLOGY; INFLAMMATORY CELL; KIDNEY MASS; KIDNEY PARENCHYMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID PEROXIDATION; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINE VOLUME; WEIGHT CHANGE; ACUTE KIDNEY INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CELL PROTECTION; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; KIDNEY; METABOLISM; PATHOLOGY; PROTEINURIA; SPRAGUE DAWLEY RAT;

ACUTE KIDNEY INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BIOMARKERS; CISPLATIN; CREATININE; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEBUXOSTAT; GLUTATHIONE; INFLAMMATION MEDIATORS; KIDNEY; L-LACTATE DEHYDROGENASE; MALE; MALONDIALDEHYDE; NITRIC OXIDE; OXIDATIVE STRESS; PROTEINURIA; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA; UROLOGICAL AGENTS; XANTHINE OXIDASE;

EID: 84969756226     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-016-1258-y     Document Type: Article

References (69)

1. Aksu U, Demirci C, Ince C (2011) The pathogenesis of acute kidney injury and the toxic triangle of oxygen, reactive oxygen species and nitric oxide. Contrib Nephrol 174:119–128
2. Antunes LM, Darin JD, Bianchi Nde L (2001) Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol Res 43:145–150
3. Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460–464
4. Bakir S, Yazgan UC, Ibiloglu I, Elbey B, Kizil M, Kelle M (2015) The protective effect of pomegranate extract against cisplatin toxicity in rat liver and kidney tissue. Arch Physiol Biochem 121:152–156
5. Bazzano T, Restel TI, Porfirio LC, Souza AS, Silva IS (2015) Renal biomarkers of male and female Wistar rats (Rattus norvegicus) undergoing renal ischemia and reperfusion. Acta Cir Bras 30:277–288
6. Beutler E, Duron O, Kelly BM (1963) Improved method for the determination of blood glutathione. J Lab Clin Med 61:882–888
7. Bories PN, Bories C (1995) Nitrate determination in biological fluids by an enzymatic one-step assay with nitrate reductase. Clin Chem 41:904–907
8. Cetin R, Devrim E, Kilicoglu B, Avci A, Candir O, Durak I (2006) Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J Appl Toxicol 26:42–46
9. Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen-Visser M (1996) Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J 9:1736–1742
10. El-Sayed IH, El-Masry SM (2003) Protection against cisplatin-induced nephrotoxicity by Cu(II)2(3,5-diisopropylsalicylate)4. Redox Rep 8:47–50
11. Fahmi AN, Shehatou GS, Shebl AM, Salem HA (2016) Febuxostat protects rats against lipopolysaccharide-induced lung inflammation in a dose-dependent manner. Naunyn Schmiedeberg’s Arch Pharmacol 389:269–278
12. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL (2007) Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 322:8–15
13. Finkel M, Goldstein A, Steinberg Y, Granowetter L, Trachtman H (2014) Cisplatinum nephrotoxicity in oncology therapeutics: retrospective review of patients treated between 2005 and 2012. Pediatr Nephrol 29:2421–2424
14. Goldman R (1967) Endogenous creatinine clearance by rats. Proc Soc Exp Biol Med 125:1021–1024
15. Granger DL, Taintor RR, Boockvar KS, Hibbs JB Jr (1996) Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol 268:142–151
16. Hannemann J, Baumann K (1988) Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: different effects of antioxidants and radical scavengers. Toxicology 51:119–132
17. Hosoya T, Ohno I (2011) A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. J Clin Rheumatol 17:S27–S34
18. Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT (2002) A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 91:1991–2002
19. Husain K, Morris C, Whitworth C, Trammell GL, Rybak LP, Somani SM (1998) Protection by ebselen against cisplatin-induced nephrotoxicity: antioxidant system. Mol Cell Biochem 178:127–133
20. Hwang SJ, Lee KH, Jang HH, Lee SR, Woo JS, Lee HJ, Jung KH, Kim W (2014) Febuxostat contributes to improvement of endothelial dysfunction in an experimental model of streptozocin-induced diabetic rats. Int J Cardiol 171:e110–e112
21. Kelm M (1999) Nitric oxide metabolism and breakdown. Biochim Biophys Acta 1411:273–289
22. Kim WK, Kwon YE (2007) Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes. Cancer Chemother Pharmacol 60:237–243
23. Kruidering M, Van de Water B, de Heer E, Mulder GJ, Nagelkerke JF (1997) Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther 280:638–649
24. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on cancer care. Cancer Chemother Pharmacol 61:903–909
25. Lee HJ, Jeong KH, Kim YG, Moon JY, Lee SH, Ihm CG, Sung JY, Lee TW (2014) Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model. Am J Nephrol 40:56–63
26. Lirdi LC, Stumpp T, Sasso-Cerri E, Miraglia SM (2008) Amifostine protective effect on cisplatin-treated rat testis. Anat Rec (Hoboken) 291:797–808
27. Malik S, Suchal K, Gamad N, Dinda AK, Arya DS, Bhatia J (2014) Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis. Eur J Pharmacol 748:54–60
28. Meier BW, Gomez JD, Kirichenko OV, Thompson JA (2007) Mechanistic basis for inflammation and tumor promotion in lungs of 2,6-di-tert-butyl-4-methylphenol-treated mice: electrophilic metabolites alkylate and inactivate antioxidant enzymes. Chem Res Toxicol 20:199–207
29. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2:2490–2518
30. Mountfield RJ, Senepin S, Schleimer M, Walter I, Bittner B (2000) Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int J Pharm 211:89–92
31. Mukhopadhyay P, Rajesh M, Pan H, Patel V, Mukhopadhyay B, Batkai S, Gao B, Hasko G, Pacher P (2010) Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med 48:457–467
32. Mukhopadhyay P, Horvath B, Zsengeller Z, Zielonka J, Tanchian G, Holovac E, Kechrid M, Patel V, Stillman IE, Parikh SM, Joseph J, Kalyanaraman B, Pacher P (2012) Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radic Biol Med 52:497–506
33. Namikoshi T, Tomita N, Fujimoto S, Haruna Y, Ohzeki M, Komai N, Sasaki T, Yoshida A, Kashihara N (2007) Isohumulones derived from hops ameliorate renal injury via an anti-oxidative effect in Dahl salt-sensitive rats. Hypertens Res 30:175–184
34. Nath KA, Norby SM (2000) Reactive oxygen species and acute renal failure. Am J Med 109:665–678
35. Nishikimi M, Appaji N, Yagi K (1972) The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen. Biochem Biophys Res Commun 46:849–854
36. Nomura J, Busso N, Ives A, Tsujimoto S, Tamura M, So A, Yamanaka Y (2013) Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK. PLoS One 8:e75527
37. Nomura J, Busso N, Ives A, Matsui C, Tsujimoto S, Shirakura T, Tamura M, Kobayashi T, So A, Yamanaka Y (2014) Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep 4:4554
38. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF (2003) An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 278:1848–1855
39. Omori H, Kawada N, Inoue K, Ueda Y, Yamamoto R, Matsui I, Kaimori J, Takabatake Y, Moriyama T, Isaka Y, Rakugi H (2012) Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol 16:549–556
40. Petersen LJ, Petersen JR, Talleruphuus U, Moller ML, Ladefoged SD, Mehlsen J, Jensen HA (1999) Glomerular filtration rate estimated from the uptake phase of 99mTc-DTPA renography in chronic renal failure. Nephrol Dial Transplant 14:1673–1678
41. Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835–842
42. Ries F, Klastersky J (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8:368–379
43. Saad SY, Najjar TA, Alashari M (2004) Role of non-selective adenosine receptor blockade and phosphodiesterase inhibition in cisplatin-induced nephrogonadal toxicity in rats. Clin Exp Pharmacol Physiol 31:862–867
44. Saad SY, Arafah MM, Najjar TA (2007) Effects of mycophenolate mofetil on cisplatin-induced renal dysfunction in rats. Cancer Chemother Pharmacol 59:455–460
45. Sahu BD, Kuncha M, Sindhura GJ, Sistla R (2013) Hesperidin attenuates cisplatin-induced acute renal injury by decreasing oxidative stress, inflammation and DNA damage. Phytomedicine 20:453–460
46. Sahu BD, Mahesh Kumar J, Sistla R (2015) Baicalein, a bioflavonoid, prevents cisplatin-induced acute kidney injury by up-regulating antioxidant defenses and down-regulating the MAPKs and NF-kappaB pathways. PLoS One 10:e0134139
47. Saleh S, El-Demerdash E (2005) Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic Clin Pharmacol Toxicol 97:91–97
48. Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Perez-Barriocanal F, Morales AI, Lopez-Novoa JM (2011) Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity. Nephrol Dial Transplant 26:3484–3495
49. Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, Soto V, Avila-Casado C, Vega-Campos IP, Nakagawa T, Zhao L, Franco M, Johnson RJ (2008a) Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Ren Physiol 294:F710–F718
50. Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Wessale JL, Zhao L, Johnson RJ (2008b) Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol 108:69–78
51. Satoh K (1978) Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 90:37–43
52. Sharma RP (1985) Interactions of cis-platinum with cellular zinc and copper in rat liver and kidney tissues. Pharmacol Res Commun 17:197–206
53. Shibagaki Y, Ohno I, Hosoya T, Kimura K (2014) Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens Res 37:919–925
54. Silici S, Ekmekcioglu O, Kanbur M, Deniz K (2011) The protective effect of royal jelly against cisplatin-induced renal oxidative stress in rats. World J Urol 29:127–132
55. Sindhu G, Nishanthi E, Sharmila R (2015) Nephroprotective effect of vanillic acid against cisplatin induced nephrotoxicity in wistar rats: a biochemical and molecular study. Environ Toxicol Pharmacol 39:392–404
56. Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Pandey R (2015) Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 66:945–950
57. Skinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG, Craft AW (1998) Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 77:1677–1682
58. Sun J, Druhan LJ, Zweier JL (2010) Reactive oxygen and nitrogen species regulate inducible nitric oxide synthase function shifting the balance of nitric oxide and superoxide production. Arch Biochem Biophys 494:130–137
59. Takeda Pharmaceuticals America (2009) Uloric (febuxostat) tablets prescribing information. Deerfield, IL. Reference ID: 2898038
60. Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, Hayashi Y, Asahi K, Terawaki H, Watanabe T (2015) Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol 19:1044–1053
61. Terada Y, Inoue K, Matsumoto T, Ishihara M, Hamada K, Shimamura Y, Ogata K, Taniguchi Y, Horino T, Karashima T, Tamura K, Fukuhara H, Fujimoto S, Tsuda M, Shuin T (2013) 5-Aminolevulinic acid protects against cisplatin-induced nephrotoxicity without compromising the anticancer efficiency of cisplatin in rats in vitro and in vivo. PLoS One 8:e80850
62. Tsuda H, Kawada N, Kaimori JY, Kitamura H, Moriyama T, Rakugi H, Takahara S, Isaka Y (2012) Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun 427:266–272
63. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644
64. Wandel C, Kim RB, Wood AJJ, Stein CM (2001) Inactive ingredients may alter bioavailability of drugs through effects on P-glycoprotein (Pgp) and CYP3A. Clin Pharmacol Ther 69:71
65. Winston JA, Safirstein R (1985) Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Phys 249:F490–F496
66. Winterberg PD, Wang Y, Lin KM, Hartono JR, Nagami GT, Zhou XJ, Shelton JM, Richardson JA, Lu CY (2013) Reactive oxygen species and IRF1 stimulate IFNalpha production by proximal tubules during ischemic AKI. Am J Physiol Ren Physiol 305:F164–F172
67. Yoshida T, Kumagai H, Kohsaka T, Ikegaya N (2014) Protective effects of relaxin against cisplatin-induced nephrotoxicity in rats. Nephron Exp Nephrol 128:9–20
68. Yuce A, Atessahin A, Ceribasi AO, Aksakal M (2007) Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol 101:345–349
69. Zager RA, Johnson AC, Becker K (2013) Renal cortical lactate dehydrogenase: a useful, accurate, quantitative marker of tubular injury and acute renal failure. PLoS One 8:e66776